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Background: Trichinella spiralis expresses paramyosin (Ts-Pmy) not only as a structural protein but also as an
immunomodulator that inhibits host complement as a survival strategy. Previous studies demonstrated that Ts-Pmy
bound to complement components C8 and C9 and inhibited the polymerization of C9 during the formation of the
membrane attack complex (MAC). The C9 binding domain of Ts-Pmy was identified within 14 amino acid residues
at the C-terminus of Ts-Pmy. The production of a monoclonal antibody that specifically targets the C9 binding site
is necessary for further studies of Ts-Pmy function and may be used as a therapeutic agent for T. spiralis infection.
Methods: In this study, a monoclonal antibody against the complement C9 binding domain of Ts-Pmy (mAb 9G3)
was produced using hybridoma technology. The binding activity of the mAb produced for recombinant or native
Ts-Pmy and the blockade of Ts-Pmy binding to C9 by the mAb were assessed by Western blot analysis. The effect of
the mAb on the viability of T. spiralis was observed by co-incubation of T. spiralis with mAb 9G3 in the presence of
complement in vitro and by passive transfer of the mAb into naive mice following T. spiralis larval challenge.
Results: mAb 9G3 was successfully produced against the C9 binding domain of Ts-Pmy and bound specifically not
only to recombinant Ts-Pmy but also to native Ts-Pmy expressed in different stages of T. spiralis, including adult
worms, newborn larvae and muscle larvae. The binding of mAb 9G3 to Ts-Pmy efficiently blocked the binding of
Ts-Pmy to human complement C9, resulting in a significant increase in the complement-mediated killing of
newborn larvae in vitro and reduced infectivity of T. spiralis larvae in mice passively transferred with the mAb.
Conclusions: mAb 9G3 is a specific antibody that binds to the C9 binding domain of Ts-Pmy and interferes with
Ts-Pmy’s complement-binding activity. Therefore, this mAb is a protective antibody that has potential as a preventive
and therapeutic agent for T. spiralis infection.
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Trichinella spiralis is a parasitic nematode that infects
humans and other mammals around the world [1]. Tri-
chinellosis, caused by the consumption of raw or under-
cooked meat contaminated with infective muscle larvae,
remains an important infectious disease on a global scale
[2]. Due to the predominantly zoonotic importance of in-
fection, new regulations for meat inspection and efficient* Correspondence: zhuxping@ccmu.edu.cn
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unless otherwise stated.quality control measures have been studied and enacted in
recent years [3]. In addition, the identification of potential
vaccine candidates, proteins and protective antibodies
has been used as an important strategy for the control of
T. spiralis infection [4,5].
The host complement system is the first line of defense
against pathogenic organisms [6]. Blocking the assembly of
complement is a pathogens principal mechanism for
escaping from host immune attack [7]. Parasitic nem-
atodes have been suggested to produce compounds
capable of inhibiting the assembly and polymerization. This is an Open Access article distributed under the terms of the Creative
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complement-mediated damage [8]. Subsequent studies
revealed that T. spiralis worms could bind to complement
components [8-10], suggesting that T. spiralis contains
proteins that bind to and potentially inhibit complement
activation to protect against host complement attack.
Paramyosin, which serves as an essential muscle protein
in invertebrates, forms the core of thick myofilaments,
which determine the length and stability of muscles [11].
In addition to being a structural protein, paramyosin has
been defined as a potential vaccine candidate against some
helminthiases [12-15]. Additional evidence demonstrated
that paramyosin played an important role as an immuno-
modulatory protein in helminth infections [12,14,16].
Paramyosin, which acts as a complement inhibitor, is cap-
able of inhibiting complement activation by binding to at
least three complement components: C1q [17], C8, and
C9 [18-20]. In our previous study, a full-length cDNA en-
coding T. spiralis paramyosin (Ts-Pmy) was cloned and
partial protection against T. spiralis infection was achieved
in mice by immunizing with recombinant Ts-Pmy (rTs-
Pmy) [16,21]. In addition, paramyosin expressed on the
outer membrane of T. spiralis plays an important role in
host immunomodulation, specifically by binding to human
complement components C8 and C9 and inhibiting the
formation of the complement membrane attack complex
(MAC), thus creating an effective strategy via which the
Trichinella parasite can evade host complement attack
[20]. Our recent results further identified the exact C9
binding site in Ts-Pmy, which was narrowed to 14 amino
acid residues within the C-terminus of Ts-Pmy between
866Val and 879Met via fragmental expression and synthe-
sized peptide screening [20]. In the presence of the syn-
thesized C9-binding peptide, human C9 polymerization
and human complement-mediated hemolytic activity were
inhibited [22].
The immune escape function of paramyosin is an ef-
fective survival strategy that allows T. spiralis to live
within its host. Blocking the complement inhibitory activ-
ity of paramyosin could be explored as an alternative strat-
egy for the control of T. spiralis infection. Monoclonal
antibodies (mAbs) targeting the complement C9 binding
site of T. spiralis paramyosin were produced and charac-
terized in this study. The viability of T. spiralis newborn
larvae (NBL) treated with one of these mAbs (mAb 9G3)
was impaired in the presence of human serum, and partial
protection against T. spiralis larval challenge was achieved
in mice passively transferred with the mAb against the
Ts-Pmy C9 binding domain.
Methods
Experimental animals
All experimental animals were purchased from the
Laboratory Animal Services Center of Capital MedicalUniversity (Beijing, China). All experimental proce-
dures were reviewed and approved by the Capital Medical
University Animal Care and Use Committee and were
consistent with the NIH Guide for the Care and Use of
Laboratory Animals.
Parasites and antigen preparation
T. spiralis (ISS 533) was maintained in female ICR mice.
Muscle larvae were recovered from infected mice using
the standard pepsin digestion method, as described pre-
viously [23]. Adult worms were collected from intestines
of mice 5–7 days after experimental infection. NBL were
obtained from fertile female adult worms cultured over-
night in RPMI 1640 containing antibiotics (100 U/ml
penicillin and 100 mg/ml streptomycin) at 37°C in the
presence of 5% CO2. Crude somatic extracts of adult
worms, muscle larvae (ML) and NBL were prepared by
homogenizing the parasites in PBS, pH 7.4, protein con-
centrations of the extract supernatants were determined
using the BCA assay (Pierce, USA).
Synthesis of Ts-Pmy C9 binding domain peptide
The C9 binding domain in Ts-Pmy was identified in our
previous study [20], and the binding peptide P25
(KHRSSVSMGKSLSSKVYVMEEGHEY, Ts-Pmy861-885),
which contains the sequence of the C9 binding site
(VSMGKSLSSKVYVM, Ts-Pmy866-879), was synthesized
using the solid-phase peptide synthesis method, purified
up to 95% via preparative RP-HPLC and verified by mass
spectrometry (Aviva Bio, China).
Production of monoclonal antibodies
To increase the immunogenicity of peptide P25, BSA
was used as a carrier. Monoclonal antibodies (mAbs)
against peptide P25 were produced using hybridoma
technology [24]. Briefly, female BALB/c mice (6–8 weeks
old) were immunized subcutaneously with 100 μg of
BSA conjugated-P25 emulsified with an equal volume of
Freund’s complete adjuvant, and boosted twice at 2-
week intervals with the same amount of BSA-conjugated
peptide emulsified with an equal volume of Freund’s in-
complete adjuvant. Three days after the final boost, the
mice were sacrificed and the spleen cells were removed
and fused with SP2/0 cells at a ratio of 5:1 with 50%
(w/v) pre-warmed (37°C) PEG2000 (Sigma–Aldrich, USA).
The hybridoma supernatants were screened for antibody
activity via ELISA using synthesized peptide P25 as the
antigen. The hybridomas secreting antibodies were cloned
by limiting dilution. The hybridoma cell clone 9G3, which
exhibited stable growth and secreted a high titer of anti-
body, was selected for further analysis and for the produc-
tion of ascites in the peritoneal cavities of BALB/c mice.
The mAb-containing culture supernatant and ascitic
fluid were collected from BALB/c mice, and the antibody
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fied by affinity chromatography using a Protein A sephar-
ose 4 FF column (GE Healthcare, USA). The subclass of
the mAb was determined using a Mouse Monoclonal
Antibody Isotyping Kit (Gibco-BRL, USA).
Immunological recognition of mAb 9G3
To determine whether mAb 9G3 enables the recognition
of recombinant or native Ts-Pmy, recombinant rTs-Pmy
was expressed in E. coli BL21 as described previously
[20]. Purified rTs-Pmy (0.5 μg), native Ts-Pmy containing
crude somatic extracts of ML, NBL or adult worms
(5 μg each) and recombinant heat shock protein-70 of
T. spiralis (Ts-Hsp70) [25] (1 μg), which served as a non-
relevant recombinant protein control, were separated via
12% SDS-PAGE under reducing conditions, and trans-
ferred onto a nitrocellulose (NC) membrane (Millipore,
USA). After blocking with 5% milk in PBS for 1 h at room
temperature, the membrane was incubated with mAb 9G3
(0.2 μg/ml) in 1% skimmed milk–PBS for 1 h at room
temperature. IRDye 800CW-labeled goat anti-mouse IgG
(LI-COR, Germany) was used as the secondary antibody.
Recognition was detected and imaged using the Odyssey
infrared imaging system (LI-COR, Germany).
To determine whether mAb 9G3 is able to recognize
native Ts-Pmy expressed on the surface of the parasite,
longitudinal sections of T. spiralis ML were prepared. The
sections were blocked with normal goat serum (1:10) for
30 min and subsequently incubated with 5 μg/ml of 9G3
in 1× PBS, pH 7.4 with 0.05% Tween-20 (PBST) for 1 h at
room temperature. Normal mouse serum was used at a
1:100 dilution as a control. The sections were washed with
PBST and subsequently incubated with a 1:200 dilution of
an Alexa Fluor 488-labeled goat anti-mouse IgG antibody
for 1 h, followed by the addition of the DAPI fluorescent
nuclear stain (1.25 μg/ml). The labeling images were ob-
tained via confocal laser scanning microscopy.
Inhibition of rTs-Pmy binding to C9 by mAb 9G3
To determine whether mAb 9G3 against the C9 binding
domain of Ts-Pmy is able to inhibit the binding of
rTs-Pmy to human complement C9, rTs-Pmy (2 μg) was
transferred onto a NC membrane (Millipore, USA) and
subsequently incubated with various amounts of mAb 9G3
(0, 2, and 4 μg) for 1 h at room temperature. BSA or mAb
7E2 (10 μg each), which is another monoclonal antibody
against rTs-Pmy1-315 that lacks the ability to bind to the
complement binding site [26], were used as controls for the
binding assay. After washing, the membrane strips were in-
cubated with human C9 (1 μg/ml) (Merck, Germany) at
37°C for 2 h and subsequently incubated with a rabbit
anti-C9 polyclonal antibody (0.2 μg/ml) (Abnova, Taiwan)
for 1 h at room temperature. IRDye 800CW-conjugated
goat anti-rabbit IgG (50 ng/ml) (LI-COR, Germany) wasused as the secondary antibody. All membrane strips were
detected and imaged using the Odyssey infrared imaging
system (LI-COR, Germany).
mAb 9G3 enhanced complement-mediated killing of NBL
in vitro
A previous study demonstrated that rTs-Pmy could bind
to complement components C8 and C9 and inhibit the
complement-mediated killing of NBL [20]. To determine
whether blocking the Ts-Pmy C9-binding domain with
mAb 9G3 would enhance the complement-mediated
killing of T. spiralis larvae, freshly obtained NBL were
pretreated with different amounts of mAb 9G3 (2, 20, or
40 μl of a 1 mg/ml solution) in a final volume of 150 μl/
well in a 96-well plate for 30 min at room temperature.
The same amount of mAb 7E2 was used as non-relevant
antibody control and normal mouse serum was used as
negative antibody control. Subsequently, 100 μl of fresh
normal human serum was added into each well as a
source of complement for an overnight incubation at 37°C
in a 5% CO2 incubator. Heat-inactivated human serum
(30 min at 56°C) served as a control. The mortality of the
NBL after the incubation was assessed based on motility
under an inverted microscope (worms without any move-
ment during 30 seconds of observation and total stretch-
out were scored as dead) [18]. The experiments were per-
formed in triplicate. The percent mortality was calculated
in the complement-treated group compared with the
heat-inactivated serum group.
Passive immunization and parasite challenge
To evaluate the possible protective function of mAb
9G3 in the defense against T. spiralis infection via block-
ing the C9-binding site of surface-expressed Ts-Pmy, a
group of six female BALB/c mice that were six to eight
weeks of age underwent passive transfer with 0.5 mg of
mAb 9G3 in a total volume of 0.1 ml per mouse 2 h be-
fore oral challenge with 500T. spiralis ML. Another boost
containing the same amount of mAb 9G3 was adminis-
tered 4 days after infection. T. spiralis-infected sera and
normal mouse sera at the same dose were used as the
positive and negative controls, respectively. Infected
mouse sera were obtained from BALB/c mice 45 days
post-infection with 500 T. spiralis ML. The reduction of
the worm burden was evaluated by counting the number
of muscle larvae collected from whole muscle tissue of
mice 45 days after the challenge infection [16].
Statistical analysis
The data were expressed as the mean ± standard error
(S.E.). Statistical analysis was performed with GraphPad
Prism software (San Diego, USA) using One-Way ANOVA.
Differences for which P < 0.05 were considered statistically
significant.
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Production and characterization of mAb 9G3
Monoclonal antibodies (mAbs) against the Ts-Pmy C9
binding site were made by fusing splenocytes from mice
immunized with the C9-binding site peptide (P25) with
SP2/0. A total of five positive hybridoma cell lines were
cloned by limiting dilution based on their high titers
against peptide P25 during ELISA, these cell lines were
designated as 5E9, 9G3, 10 F10, 14C10, and 14H9. The
subclasses of all of these mAbs were determined to be
IgG1. One of these antibodies, mAb 9G3, exhibited the
highest absorbance value during ELISA and also exhib-
ited stable growth. Therefore, this clone was selected for
further study. The 9G3 hybridoma cells were injected
into BALB/c mice for ascitic fluid production. The anti-
body titers of the cell culture supernatants and the ascitic
fluid against P25 were 1:3 200 and 1:516 000, respectively.
Western blot analysis revealed that mAb 9G3 recognized
not only the full-length recombinant rTs-Pmy protein
(~110 kDa) but also the native protein in adult and larval
worms of T. spiralis (Figure 1).
Immunolocalization analysis
An immunofluorescence assay demonstrated that the
anti-Ts-Pmy C9 binding site mAb 9G3 could strongly
recognize native Ts-Pmy expressed on the surface of ML
longitudinal sections (Figure 2). This finding is consist-
ent with our previous study, which demonstrated that
Ts-Pmy was expressed on the outer membrane of the cu-
ticle of NBL and adult worms [20]. No significant staining
was observed using normal mouse serum at the same di-
lution. All larvae exhibited nuclei that stained with DAPI.
mAb 9G3 blocks rTs-Pmy binding to C9
The binding of rTs-Pmy to C9 was significantly inhibited
by mAb 9G3 in a dose dependent manner. When the
amount of mAb 9G3 was increased to 4 μg, the antibody
nearly completely blocked the binding of rTs-Pmy (2 μg)
to C9 (1 μg/ml) (Figure 3). As expected, the negativeFigure 1 Recognition of recombinant and native Ts-Pmy (~102 kDa) b
Lane 1, adult extracts (5 μg); Lane 2, ML extracts (5 μg); Lane 3, NBL extract
Lane 6, irrelevant recombinant Ts-Hsp70 control (1 μg). After transfer of the
incubated with mAb 9G3 (0.2 μg/ml). IRDye 800CW-labeled goat anti-mouscontrols mAb 7E2 and BSA exerted no inhibitory effect
on the binding of rTs-Pmy to C9, even at high concen-
trations (10 μg).
Enhanced complement-mediated killing of NBL incubated
with mAb 9G3
A previous study demonstrated that Ts-Pmy plays an im-
portant role in protecting Trichinella parasites, particu-
larly NBL, from being attacked by host complement by
binding to C8 or C9 [18]. In this study, NBL were incu-
bated with mAb 9G3 to block the binding site of native
surface-expressed Ts-Pmy for complement C9. The NBL
were xthen incubated with fresh human serum as a
source of complement. The results demonstrated that
the complement-mediated killing of NBL was signifi-
cantly enhanced by incubation with mAb 9G3 in a dose-
dependent manner compared with the normal mouse
serum group. When up to 40 μl of a 1 mg/ml solution
of mAb 9G3 was added, 32.9% of NBL were killed com-
pared with 4.3% of NBL in the normal mouse sera con-
trol group (40 μl added). No significant increases in larval
mortality were observed in the group incubated with the
monoclonal antibody mAb 7E2 until the amount of mAb
7E2 reached 40 μl of a 1 mg/ml antibody solution, how-
ever, the mortality (10.8%) of this treatment was much
lower than that caused by the same amount of mAb 9G3
(32.9%) (Figure 4).
Protection against challenge infection in mice adoptively
transferred with mAb 9G3
The challenge results demonstrated that after the passive
transfer of 0.5 mg of mAb 9G3 in a total volume of 100 μl
to BALB/c mice, each mouse exhibited a 42.6% reduction
in muscle larvae burden compared with the normal mouse
sera transfer control (P < 0.01) (Figure 5). As a positive
control, mice that received the same volume of T. spiralis-
infected mouse sera (100 μl) displayed a 34.3% reduction
in muscle larvae burden (P < 0.05). The results presented
here demonstrate that mAb 9G3 provides protectivey mAb 9G3, as demonstrated by Western blot. M, protein marker;
s (5 μg); Lane 4, rTs-Pmy with a His-tag (0.5 μg); Lane 5,BSA(1 μg);
proteins to the nitrocellulose membrane, the membrane was
e IgG was used as the secondary antibody.
Figure 2 Immunofluorescent detection of native Ts-Pmy expressed on the surface of T. spiralis ML using the anti-Ts-Pmy C9 binding
domain mAb 9G3. The longitudinal section of ML was incubated with mAb 9G3 (5 μg/ml), and subsequently incubated with Alexa Fluor
488-labeled goat anti-mouse IgG antibody (in green) or DAPI to label nuclei (in blue) (A). Normal mouse serum at the same dilution was used as
a negative control (B). The scale bars represent 15 μm.
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better than that induced by T. spiralis-infected sera.
Discussion
Due to its ability to rapidly recognize and eliminate mi-
croorganisms, the complement system is an essential
and efficient component of the human innate immune
system [6]. During co-evolution with their hosts, para-
sites developed a multitude of mechanisms for evading
attacks by the host immune system. Parasite-produced
compounds that bind to and inactivate the host’s comple-
ment components have been identified in several parasites
as effective immune escape mechanisms [4,6-8,16,17].
Paramyosin is one of the most important molecules pro-
duced by helminths to defense from the host’s comple-
ment attack [10,12,14]. In particular, T. spiralis-produced
paramyosin (Ts-Pmy) was demonstrated to bind to human
complement components C8 and C9 and subsequently in-
hibit the polymerization of C9 during the formation of the
membrane attack complex (MAC), thus protecting Trichi-
nella larvae from being attacked by the host complement
system [20]. The complement C9 binding domain of
Ts-Pmy was identified within 14 amino acid residuesFigure 3 Inhibition of rTs-Pmy binding to C9 by the addition of differ
(2 μg) was transferred onto a NC membrane and incubated with various am
mAb 9G3 (4 μg). Lane 4: BSA (10 μg) and Lane 5: irrelevant mAb 7E2 contr
C9 (1 μg/ml) at 37°C for 2 h and subsequently incubated with rabbit anti-C
800CW-labeled goat anti-rabbit IgG (50 ng/ml) was used as the secondary(866Val-879Met) at the C-terminus of Ts-Pmy [22]. Theor-
etically, a specific antibody targeting the complement
binding domain of Ts-Pmy should block the binding of
Ts-Pmy to human complement, exposing the parasites to
attack by the host complement system. Therefore, such an
antibody would be a protective antibody against T.spiralis
infection.
To produce specific antibodies targeting the C9 bind-
ing domain of Ts-Pmy, a 25 amino-acid peptide (P25)
covering Ts-Pmy861-885, including the 14 amino-acid
sequence of the C9 binding site (VSMGKSLSSKVYVM,
Ts-Pmy866-879), was synthesized and used to immunize
mice for the production of monoclonal antibodies. Al-
though the C9 binding site in Ts-Pmy was narrowed to
14 amino acid residues (866Val-879Met), the extension of
the amino acid sequence on both sides up to 25 amino
acids may increase the immunogenicity of the peptide.
The production of monoclonal antibodies against syn-
thetic peptides is a versatile tool in the molecular and
functional analysis of proteins [27-29]. However, some
factors should be considered during the design of pep-
tides for the production of anti-peptide antibodies, in-
cluding the length of the peptides, the location of theent amounts of mAb 9G3, as determined by Western blot. rTs-Pmy
ounts of mAb 9G3. Lane 1: PBS only; Lane 2: mAb 9G3 (2 μg); Lane 3:
ol (10 μg). After washing, the membrane was incubated with human
9 polyclonal antibody (0.2 μg/ml) for 1 h at room temperature. IRDye
antibody.
Figure 4 Enhanced complement-mediated killing of T. spiralis
NBL incubated with mAb 9G3. NBL were pretreated with different
volumes (2 μl, 20 μl and 40 μl) of mAb 9G3 (1 mg/ml), the irrelevant
mAb 7E2 (1 mg/ml) or normal mouse serum prior to the addition of
100 μl of normal human serum. Heat-inactivated human serum
served as a control. The mortality of the NBL was assessed under an
inverted microscope. The results are presented as the arithmetic
mean ± standard error (SE) from triplicate experiments. **p < 0.01,
*p < 0.05 compared with the normal mouse sera control.
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peptides [30]. In this study, the synthesized P25 peptide
was conjugated to BSA to increase its immunogenicity.
To exclude the possible production of mAbs against the
conjugated BSA, the hybridoma culture supernatantsFigure 5 Protection of mice against T. spiralis larval challenge
after passive transfer of mAb 9G3 or T. spiralis-infected mouse
sera. Larvae were collected from the muscles of BALB/c mice
following the passive transfer of mAb 9G3 and a subsequent challenge
infection with 500 T. spiralis larvae. The results are presented as the
arithmetic mean of six mice per group ± standard error (SE). **p < 0.01,
*p < 0.05 compared with mice transferred with normal mouse sera.were screened directly against synthesized peptide as an
antigen coated on plate during ELISA. Among the five
stable hybridoma cell lines, only the stable cell line 9G3
secreted an antibody that recognized not only full-length
recombinant Ts-Pmy, but also native Ts-Pmy in T. spiralis
adult and larval (ML and NBL) extracts. Immunolocaliza-
tion on longitudinal sections of ML demonstrated that
mAb 9G3 also recognized Ts-Pmy expressed on the sur-
face of Trichinella larva, which is consistent with our pre-
vious study that demonstrated that Ts-Pmy was present
on the outer membrane of the cuticle of adults and NBL
[18]. The universal distribution of Ts-Pmy in different de-
velopmental stages of T. spiralis provides a more adequate
experimental basis for the role of paramyosin as a poten-
tial modulator of the host immune system during different
parasitic stages.
In addition to the specific binding of mAb 9G3 to na-
tive Ts-Pmy expressed in different developmental stages
of T. spiralis, this antibody also efficiently inhibits the
binding of Ts-Pmy to human complement C9, suggest-
ing that this antibody possesses the ability to functionally
block the complement binding activity of Ts-Pmy. To
determine whether blocking the C9-binding domain of
Ts-Pmy would inhibit the protection employed by Ts-
Pmy against complement attack and therefore enhance
the complement-mediated killing of T. spiralis parasites,
we incubated T. spiralis NBL with mAb 9G3 before add-
ing fresh human serum as a source of complement. NBL
were chosen as a target for the complement killing assay
because the NBL stage is the stage that migrates through
the blood and lymphatic circulation to muscular tissue
and is exposed directly to the host immune system, thus,
this stage should develop sophisticated abilities to evade
complement attack, such as complement-binding Ts-Pmy
[18], as a survival strategy [5]. Blocking Ts-Pmy on the
surface of T. spiralis NBL by incubating live NBL with
mAb 9G3 resulted in significantly enhanced complement-
mediated killing of NBL in the presence of fresh human
serum in vitro, suggesting that blocking the C9-binding
domain of Ts-Pmy with mAb 9G3 efficiently inhibits the
function of Ts-Pmy that protects the parasite from being
attacked by host complement. After incubation with mAb
7E2, which is a mAb that binds to the N-terminus of
Ts-Pmy but not to the complement-binding domain of
Ts-Pmy,T. spiralis larvae exhibited similar levels of viability
or reduced levels of viability when large amounts of anti-
body were added, however, the complement-mediated
killing of larvae was much lower than that induced
by incubation with mAb 9G3 (Figure 4). The limited
complement-mediated larval killing by a mAb that does
not bind to the complement-binding domain of Ts-Pmy
(mAb 7E2) may be a result of complement activation
through the classic antibody-mediated pathway. The sig-
nificantly higher complement-mediated larval killing by
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mAb that is not related to the complement binding site of
Ts-Pmy further indicates that Ts-Pmy protects Trichinella
parasites from being attacked by host complement by inhi-
biting the alternative pathway of complement activation [6].
Impaired infectivity of T. spiralis parasites was also ob-
served in mice passively transferred with the anti-C9 bind-
ing domain of Ts-Pmy mAb 9G3. The protection level
induced by mAb 9G3 (42.6%) was higher than that elicited
by T. spiralis infected mouse sera (34.3%) (Figure 5).
This study further elucidates the mechanism of nema-
tode paramyosin involved in the immunomodulation of
host immune response and the specific monoclonal anti-
body against paramyosin’s functional domain could be
used as a therapeutic or preventive agent for Trichinello-
sis. However, except for the binding site for C9 on Trichi-
nella-secreted paramyosin, there may be more binding
sites for other components of complement that may also
contribute to evading complement attack for the survival
of parasite in the host, which is under investigation.
Conclusions
In summary, in this study, we demonstrated that the
monoclonal antibody 9G3 that targets the complement
C9 binding domain of Ts-Pmy could efficiently block the
complement inhibitory activity of Ts-Pmy, resulting in a
significant increase in the complement-mediated killing
of newborn larvae in vitro and reduced infectivity of
T. spiralis larvae in mice passively transferred with the
mAb. Therefore, mAb 9G3 is a protective antibody that
has potential as a preventive and therapeutic agent for
T. spiralis infection.
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